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INTRODUCTION
Atrial fibrillation (AF) increases the risk of stroke and sys-
temic thromboembolism. A hypercoagulable state in AF is 
reflected by elevated von Willebrand factor (vWF), D-dimer, 
and thrombin generation (TG), as well as increased platelet 
activation [1]. The usefulness of several biomarkers in stroke 
and bleeding risk prediction among AF patients, in particular 
N-terminal pro–B-type natriuretic peptide (NT-proBNP) and 
high-sensitivity cardiac troponin I (cTnI-hs), has been dem-
onstrated, although practical implications of this strategy are 
uncertain [2]. 
We sought to assess the relations of four such markers: 
cTnI-hs, cystatin C, vWF, and NT-proBNP, with prothrombotic 
alterations in AF patients.
METHODS
We investigated 65 patients with AF free of myocardial infarc-
tion or venous thromboembolism within the previous three 
months, with creatinine clearance ≥ 15 mL/min, and without 
liver cirrhosis, known cancer, or acute infection. Detailed 
methodology of the study was presented previously [3]. Vi-
tamin K antagonists and low-molecular-weight heparin (the 
last dose ≥ 12 h) were discontinued before the blood draw. 
The study was approved by the Bioethical Committee, and 
patients gave informed consent.
Venous blood samples were taken with minimal stasis, 
and routine blood tests were performed by standard labora-
tory techniques. Electrochemiluminescence immunoassay 
(Roche Diagnostics, Mannheim, Germany) was used to 
measure NT-proBNP levels. The ARCHITECT i1000SR and 
ARCHITECT ci8200 (Abbott Laboratories, Abbott Park, IL, 
USA) were used to assess cTnI-hs and cystatin C levels, 
respectively. Latex immunoassay using a STAR coagulation 
instrument (Diagnostica Stago, Asnières, France) was used 
to measure vWF antigen. 
Assessment of TG profile was performed as described [4]. 
Briefly, corn trypsin inhibitor was added to citrated plasma 
(a final concentration of 0.1 mg/mL), and then samples 
(80 µL each) were mixed with relipidated tissue factor to 
achieve a final concentration of 5 pM and with a 2.5 mM 
Z-GGR-AMC/90 mM CaCl2 solution in Hepes-buffered sa-
line to achieve a 417 µM and 15 mM final concentration, 
respectively, followed by incubation at 37°C for 3 min. Lastly, 
a phospholipid vesicles solution in Hepes-buffered saline 
was added to samples to achieve 20 µM final concentration, 
thereby initiating TG. Hydrolysis of the 7-amino-4-methylcou-
marin substrate at 370 nm excitation and 460 nm emission 
wavelengths was followed for 3600 s. A calibration curve 
built by sequential dilutions of human thrombin into pooled 
multi-donor plasma from healthy individuals was used to 
convert substrate hydrolysis to thrombin concentration. We 
used the BioTek Synergy 4 plate reader and Gen5 plate reader 
software for analysis (BioTek, Winooski, VT, USA). 
Statistical analysis
Quantitative variables were presented as the mean (standard 
deviation) or median (interquartile range). Normal distribution 
was assessed using the Shapiro-Wilk test. Quantitative vari-
ables were compared using Student t-test or Mann-Whitney 
U test, and correlations were tested using a linear Pearson 
correlation or Spearman’s rank test, as appropriate. We di-
vided patients into three groups based on tertiles of cTnI-hs 
levels, and into four groups based on the CHA2DS2-VASc 
score. Normally distributed data in three or more groups 
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were compared using one-way ANOVA (in homogeneity of 
variance) or Welch ANOVA (otherwise). Tukey’s HSD test 
was used to assess pairwise comparisons. For comparison of 
non-normally distributed variables in three or more groups, 
the Kruskal-Wallis test was used, and for pairwise compari-
sons the Kruskal-Wallis test with the Bonferroni correction 
was used. Qualitative variables were described by number 
(frequency) and compared by c2 test or Fisher exact test. 
To assess predictors of peak thrombin concentration we 
performed linear regression analysis. R2 was calculated, and 
assessment of model adequacy using F test was performed. 
P values of < 0.05 were considered statistically significant. 
IBM SPSS Statistics (version 24.0, IBM Corp., Armonk, NY, 
USA) was used to perform statistical analysis.
RESULTS AND DISCUSSION
The current study group included 65 patients aged 
69.8 ± 9.9 years (41.5% women), who had mostly perma-
nent AF (53.8%) (Suppl. Table 1 — see journal website). 
CHA2DS2-VASc score ≥ 2 was observed in 93.8% of patients. 
Patients in the third cTnI-hs tertile were older than those in 
the first and second tertiles (all p < 0.005). Patients in the first 
cTnI-hs tertile had a higher haemoglobin concentration than 
those in the third cTnI-hs tertile (p = 0.02) (Suppl. Table 2 
— see journal website). In the whole group cystatin C was 
correlated with cTnI-hs (r = 0.34, p = 0.005), but not with 
NT-proBNP (r = 0.12, p = 0.33).
CHA2DS2-VASc score was positively correlated with 
cTnI-hs (R = 0.47, p < 0.001) and cystatin C (r = 0.39, 
Figure 1. Associations of CHA2DS2-VASc score with high-sensitivity cardiac troponin I (cTnI-hs; A) and cystatin C (B) in patients 
with atrial fibrillation (AF). Correlation between time to peak thrombin generation and von Willebrand factor (vWF) in patients 
with AF (C); Ag — antigen. Thrombin generation among sample patients from different cTnI-hs tertiles (D). Values are presented 
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p = 0.001), with a similar trend for NT-proBNP (R = 0.22, 
p = 0.07). cTnI-hs and cystatin C (Fig. 1A, B) were higher 
in subjects with the highest CHA2DS2-VASc score when 
compared to patients with the lowest CHA2DS2-VASc score. 
No such associations were observed for NT-proBNP, vWF, 
creatinine, or TG parameters. There was no correlation be-
tween vWF and CHA2DS2-VASc score, cTnI-hs, cystatin C, or 
NT-proBNP (data not shown).
Analysis of TG showed that lag phase and endogenous 
thrombin potential did not correlate with cTnI-hs, NT-proBNP, 
or cystatin C. Time to peak thrombin generation was cor-
related with vWF (Fig. 1C) and tended to correlate with 
cTnI-hs (r = –0.22, p = 0.08), but not with NT-proBNP or 
cystatin C. Importantly, peak thrombin concentration cor-
related with cTnI-hs and was associated with cTnI-hs tertiles 
(R = 0.37, p = 0.003, Fig. 1D) but not with NT-proBNP, 
cystatin C, or vWF. Peak thrombin concentration was not 
related to glomerular filtration rate (GFR) and age (r = 0.04, 
p = 0.73 and r = 0.10, p = 0.44, respectively). In linear 
regression analysis peak thrombin concentration was pre-
dicted by cTnI-hs (unstandardised coefficient B: 17.09; 
95% confidence interval [CI]: 0.06–34.11, p = 0.049) but 
not GFR (B: 0.43; 95% CI: –2.02–2.88; p = 0.73) or age 
(B: 1.84; 95% CI: –2.86–6.54; p = 0.44). Peak thrombin 
concentration was predicted by cTnI-hs (B: 27.30; 95% CI: 
7.15–47.45; p = 0.009), after inclusion of GFR in the model 
(B: 2.55; 95% CI: –0.26–5.37; p = 0.074), R2 = 0.11, F = 3.73, 
p = 0.029.
Our study shows that peak thrombin concentration is as-
sociated with cTnI-hs in AF patients, suggesting that the most 
sensitive TG parameter is associated with processes leading 
to myocardial injury, strain, or ischaemia in this common ar-
rhythmia. This sensitivity of peak thrombin, but not endogenous 
thrombin potential, is best reflected by the observation that in 
patients with acute coronary syndromes at admission and six 
months later the sole elevated TG marker is peak thrombin when 
compared to controls [5]. Peak thrombin generated, together with 
shorter times to maximum levels, are well-established features 
of hypercoagulable states and may be useful in the assessment 
of bleeding and thromboembolic risk [6]. Our preliminary study 
suggests that cardiac troponins better reflect TG in AF compared 
with other biomarkers. In AF elevation of cTnI-hs is related to car-
diac disease, including heart failure and coronary artery disease, 
the risk factors for stroke in AF, being associated with the severity 
of myocardial ischaemia and/or injury [7, 8]. Troponin release 
may also occur during tachyarrhythmias and bradyarrhythmias 
frequently observed in patients with AF [9].
We confirmed that cTnI-hs and renal function param-
eters are associated with CHA2DS2-VASc score [10, 11] and 
that higher AF burden is associated with elevated troponin 
levels [7]. 
Our study supports biomarker-based risk stratification 
among patients with AF [2, 12]. Current results and our 
previous observations indicate that cardiac troponin and 
NT-proBNP may be implicated in similar pathogenic pathways 
leading to faster and/or enhanced TG, which significantly 
contributes to a hypercoagulable state in AF [3]. These two 
biomarkers and associated pathways may be common with 
those noted in ischaemic stroke [13].
The current study has several limitations. First, the study 
group was small. Secondly, TG can be determined using 
various assays, including the use of different concentrations 
of reagents in calibrated automated thrombograms. We did 
not measure anti-Xa activity in our study. It is unclear whether 
anticoagulated AF patients show similar associations between 
TG variables and other biomarkers.
The current study provides insights into relations of cir-
culating biomarkers with thromboembolic risk and thrombin 
generation in patients with AF.
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